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Previous studies in breast, colon, and head and 
neck cancer have indicated a benefit to one hour se¬ 
quencing of methotrexate (MTX) and 5-fluorouracil (FUra). 
However, in vitro studies in human breast cancer cell lines 
suggest optimal tumor toxicity is achieved when ? O.lxM MTX 
precedes FUra by 18 to 24 hours. A clinical toxicity 
study was carried out to assess whether 24 hour sequenced 
MTX-FUra with leucovorin (LV) rescue could be tolerated 
and to determine if oral MTX could sustain serum concentra¬ 
tions of > 0.1*M over 24 hours. Seven patients with ad¬ 
vanced malignancy were treated with 21 courses of treatment; 
? 
MTX 50 mg/m“ p.o. every six hours for five doses; FUra 600 
2 
mg/m i.v. at one hour after the fifth does of MTX; LV 
2 
10 mg/m p.o. every six hours for six doses begun six hours 
after the fifth MTX dose. All patients had received prior 
MTX and six out of seven had been previously treated with 
one hour sequenced MTX-FUra plus LV. Performance status 
in six out of seven patients was^2(ECOG). No patient 
was entered with leukopenia or creatinine clearance < 65ml/min. 
Serum MTX levels were measured during all 21 courses of 
therapy. Mean concentrations one hour prior to the fifth 
dose of MTX were 1.07 —. 74>tM and were 2.10 — . 92*M one hour 
after the fifth MTX dose. Four of seven patients received 
more than two courses at an average interval of 23 days be- 
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tween courses. No toxicity occurred in 38% of treatment 
courses; nylld to moderate leukopenia and mucositis occurred 
in 29% and 38% of courses, respectively. Toxicity was re¬ 
lated to re-treatment interval and not cumulative drug 
dose or elevated serum MTX levels. Based on these clinical 
results, the treatment protocol appears to be well tolerated 
and a larger trial evaluating 24 hour sequenced MTX-FUra 





In 1981, cancer of the breast was the third leading 
cause of cancer death. Occurring almost exclusively in 
women, (99% of cases), it is both the leading cancer type 
and the major cause of cancer death among women (1). 
Breast cancer kills more women ages 40-44 than any other 
disease, and one out of 11 women can expect to develop 
breast cancer in her lifetime (2). 
Over the past 50 years, there has been no substantial 
change in survival rates (2). In an effort to elucidate 
breast cancer risk factors and to evaluate the various 
treatment modalities, there has been a great amount of 
epidemiological and experimental data collected. As a 
result, new concepts of the disease are being developed 
with new therapeutic approaches following. The most im¬ 
portant new concept to emerge is the fact that breast cancer 
is actually a heterogeneous group of diseases with vary¬ 
ing natural histories and time courses (3). 
The cause of the disease is unknown, but it most 
likely depends on the relationships between a number of 
factors including age, genetic and familial variables, diet, 
geographic area of residence, reproductive history, virus 
exposure, radiation, and endocrinological environment. There 
is a steady rise in breast cancer risk during premenopausal 
years beginning in the third decade of life, a temporary 
dip at menopause, and a continued rise at a slower rate 
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after menopause (4). Women with a previous personal 
history or a familial history of breast cancer have an 
increased risk of developing the disease (5,6). Also 
associated with an increased risk are early menarche 
and late natural menopause, nulliparity or a delay of 
first full term pregnancy until after age 30, excessive 
irradiation to the whole body or breast, fibrocystic 
disease of the breast, and large body size especially 
with increased animal fat intake (7). Bilateral oophor¬ 
ectomy before age 35 decreases the incidence of breast 
cancer in parous and nulliparous women (8), whereas 
estrogen replacement therapy and oral contraceptive use 
increases the risk, although this is still being debated 
(9,10) . 
As stated previously, despite extensive research 
and new developments in technology and pharmacology 
there has been little change in breast cancer mortality 
rates over the past several decades. Five-year survival 
rates for all stages of breast cancer in the 1950's were 
60% while they were 65% in the 1970's. Between the 1940's 
and the 1970's, five-year survival rates for breast cancer 
diagnosed in the localized stage have increased from 78% 
to 85%. Cancer that has spread to the axillary lymph nodes 
now has a five-year survival rate of 56% up from 50% in 
1950, while breast cancer with distant metastases has a five- 
year survival rate of 10% as opposed to 21% in the early 
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1950's. Ten-year survival rates parallel these trends (2). 
Prognostic variables that influence these survival 
rates include tumor size, histologic findings and the 
presence or absence of metastases in axillary lymph nodes. 
For patients treated with radical surgery, the most impor¬ 
tant single prognostic factor is the absolute number of 
axillary lymph nodes involved with tumor as shown in Table 
1 (3). The probability of node involvement increases with 
increasing tumor size, but tumor size affects survival 
rates independently as well. In patients with one to three 
positive nodes, the five-year recurrence rate in those with 
lesions one to two cm in diameter on physical examination 
is 44% as opposed to 63% in patients whose lesions measure 
six cm in diameter (11) . However, there is a group of pa¬ 
tients with very large lesions who delayed seeking treat¬ 
ment more than one year who show no evidence of nodal me¬ 
tastases and have a comparatively low recurrence rate. Al¬ 
though it seems reasonable to expect that the duration of 
symptoms would correlate with progression, this does not 
seem to be the case. This suggests a varied population of 
patients with breast cancer—those with tumors that grow 
large within the breast but do not metastasize and thus 
remain curable even with delayed consultation, and those 
with tumors that metastasize very quickly before there is 
much growth in the breast and therefore become incurable 
even with early consultation (3) . 
Nevertheless, generally speaking, the size of the tu- 
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mor significantly affects prognosis. Eighty percent of 
patients who have tumors less than 1 cm in diameter, as 
compared to 45% of patients with 5-7.5 cm tumors, are 
alive ten years after diagnosis (3). Early detection 
while the tumor is small and before distant metastases occur 
is at present the most important hope for breast cancer 
control. 
The percentage of breast cancers diagnosed in a 
localized stage has increased from 38% to 47% between 
the 1940's and 1970's. Breast self-examination and mam¬ 
mography have contributed to this earlier detection. 
Both the Health Insurance Plan of New York study and the 
National Cancer Institute/American Cancer Society Breast 
Cancer Detection Demonstration Projects showed the importance 
of the combination of physical examination and mammography 
in breast cancer screening. In the Breast Cancer Detection 
Demonstration Project the number of breast cancers diag¬ 
nosed in the localized stage reached greater than 70% (2). 
Mammographic equipment and techniques have developed to 
require lower radiation dose exposure, but there are still 
concerns over the possible danger of radiation-induced 
breast cancer. At present, indications for mammographic 
screening include evaluation of high risk patients and pa¬ 
tients with prior breast cancer (12). 
Breast self-examination at monthly intervals is 
crucial to cancer detection. Over 90% of breast cancers 
are discovered by women themselves (2). Since 50% of masses 
0.6-1.0 cm are palpable (13) they are often discovered 
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while still small. It is through breast self-examination 
that the rapidly growing cancers that develop between annual 
m 
mammograms and are most likely to metastasize will be de¬ 
tected (14,p.209). The screening of asymptomatic women 
and early breast cancer detection has shown preliminary im¬ 
provement in survival rates, but it is as yet unclear 
whether this represents the result of lead time bias or in 
fact will lead to a decrease in the number of deaths from 
breast cancer(3). 
A variety of treatment options are available to women 
with breast cancer. Local therapy is the oldest form of 
treatment with radical resection of the breast, pectoralis 
muscles, and regional lymph nodes being the standard and 
traditional treatment since Halsted's and Meyer's radical 
mastectomy results in 1894 (14,p.257). This approach as¬ 
sumed an orderly spread from the tumor to lymph nodes and 
then to distant sites of the body. However, a biological 
conception of cancer spread has superseded this anatomical 
approach with the realization that tumor cells can dissemi¬ 
nate through the blood and lymph systems in a variety of 
less orderly ways. It is also true that some cancers may be 
diagnosed in a very early phase, before the invasiveness 
that makes radical surgery appropriate. 
These new concepts of growth and spread of cancer 
coupled with the fact that mortality rates have not decreased 
despite radical surgery have sharpened the focus on thera- 
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peutic alternatives. These alternatives have been statis¬ 
tically evaluated in terms of morbidity of treatment method, 
the rate of local recurrence, the duration of symptom- 
free survival, and the total duration of survival. It 
should be noted that extreme variation in the natural history 
of breast cancer in terms of growth rate and length of pa¬ 
tient survival makes evaluating new therapies very diffi¬ 
cult. 
Alternative approaches to breast cancer treatment include 
less radical surgery—the modified radical mastectomy, sim¬ 
ple mastectomy and lumpectomy--all with or without radia¬ 
tion therapy. When analyzed in a series of prospective 
trials, no single approach or combination of surgery and 
radiation therapy proved more valuable in terms of survival 
results than any of the others (3,15,14,p.283). The obvious 
conclusion is that the more radical and deforming surgery 
no longer needs to be accepted as the standard treatment. 
Radiation therapy results show a decrease in local recurrence 
but do not show a survival advantage. However, surgical 
resection of lymph nodes and radiation of nodal metastases 
seem to be therapeutic equivalents (16) . 
Failure of therapy seems to correlate with the stage 
of disease rather than with a particular form of treatment. 
Thus the extent of the disease must be considered a major 
determinant of prognosis. It is not possible, however, 
to determine which patients have systemic disease at the 
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time of diagnosis since micrometastases are as yet unde¬ 
tectable. #0ne third of patients without palpable nodes 
will have histologic evidence of tumor invasion in lymph 
nodes and one third of patients with palpable nodes will have 
no evidence of tumor there (3). Even patients with histo¬ 
logically negative axillary lymph nodes cannot be assumed to 
have local disease since in these cases there is at least a 
24% treatment failure rate (17). Therefore, prophylactic 
treatments beyond local therapy have been developed to 
destroy the presumed occult metastases. 
Adjuvant endocrine therapy, including ovarian radia¬ 
tion and oophorectomy, has been used for a long time pri¬ 
marily in premenopausal women. It has generally shown marginal 
value in premenopausal patients in lengthening the time to 
first recurrence and, in some studies, in prolongation of 
survival. The addition of prednisone seems to enhance the 
value of ovarian ablation (18). These studies were done 
before estrogen receptors were taken into account. Con¬ 
trolled trials correlated with estrogen receptor status 
are now underway to evaluate adjuvant endocrine therapy 
including ovarian ablation, estrogens, and anti-estrogen 
drugs in pre- and postmenopausal women (19). 
Adjuvant chemotherapy has generally been used in pa¬ 
tients with operable disease and histologically positive 
axillary lymph node involvement. Regimens administered 
one to two years post mastectomy have shown impressive re- 
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suits in the past five years. The most dramatic benefits 
are seen in premenopausal women given a combination of 
m 
cyclophosphamide (CTX), methotrexate (MTX), and 5-fluoro- 
uracil (FUra), monthly for one year. After four years 
these patients had a statistically significant advantage 
in disease-free and absolute survival. Nevertheless, 
almost 50% of the treated premenopausal patients with four 
or more positive nodes have relapsed within four years 
(20,21). It may be that adjuvant chemotherapy is merely 
delaying recurrence rather than increasing cure rate. The 
combination of CTX, MTX, FUra with vincristine and predni¬ 
sone (CMF-VP) has benefited both pre- and postmenopausal 
patients with four or more positive axillary nodes U2). 
There is at this point no established role of early sys¬ 
temic cytotoxic chemotherapy in the treatment of patients 
with negative nodes. The potential late complications of 
adjuvant chemotherapy are as yet unknown. 
Other adjuvant therapies such as immunotherapy or 
the combination of endocrine-, immuno-, and chemo-therapies 
have yet to be studied conclusively. The combination of 
endocrine- and chemo-therapy seems promising; cytotoxic 
chemotherapy could be active against both those hormone- 
sensitive cells stimulated into a cycling state by endocrine 
therapy and the overgrowth of hormone-insensitive cells 
that result from the endocrine therapy (18). Adjuvant 
therapy is important as a therapeutic back-up to experi- 
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mentation with less extensive surgery. 
Regardless of the initial treatment for women with 
breast cancer, the majority will eventually have disseminated 
disease (14,p.361). Once distant metastases are present, 
cure is rare with the present treatments available. Survi¬ 
val can be prolonged, however, and some of the symptoms of 
advanced cancer can be relieved with hormonal therapy, 
chemotherapy, or a combination of these (3). 
Hormonal manipulation has been used for advanced breast 
cancer since 1895 when oophorectomy was found to produce 
tumor regression (14,p.367). The recent addition of antiestro 
gens and aminoglutethimide plus glucocorticoid, with their 
limited toxicity, may render the more traditional forms of 
endocrine ablation, (oophorectomy, adrenalectomy, and hypo- 
physectomy), unnecessary. Premenopausal women benefit most 
from ablative therapy followed by antiestrogens or androgens. 
Postmenopausal women show the best response to antiestrogen 
or estrogen therapy (14,p.396,23,24). 
The ability to assay for estrogen receptors has made 
the response to hormonal therapy more predictable. While 
the response rate to endocrine therapy for the general pa¬ 
tient prior to selection by estrogen receptor status was 
approximately one third, the reponse rate in estrogen re¬ 
ceptor positive women is now 50% to 60% and is less than 
10% in estrogen receptor negative women (25). The women 
who would be expected to respond to endocrine therapy 
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by their clinical characteristics are also those who are 
more frequently estrogen receptor positive and who have 
higher receptor levels. This includes postmenopausal 
more than premenopausal women, older women in both the 
pre- and postmenopausal group, those women with long 
disease-free intervals (slower growing disease) , and 
those women with metastatic disease in bone or soft tissue 
as opposed to the viscera (3). 
Cytotoxic chemotherapy is effective against advanced 
breast cancer and should be considered in women who are 
estrogen receptor negative, in women who fail to respond 
to endocrine therapy, and in women whose disease is rapid¬ 
ly progressing and life-threatening. Cytotoxic drugs are 
active against rapidly dividing cells which include the 
tumor as well as host tissues such as bone marrow, gastro¬ 
intestinal tract lining, skin, and hair. The acute toxicities 
of bone marrow suppression, nausea, vomiting, diarrhea, 
stomatitis, alopecia, and increased fatiguability are 
the chief limitations to the use of chemotherapy. Short¬ 
term side effects are generally related to dose; however, dose re¬ 
duction is often limited because of the narrow therapeutic 
index. Long-term side effects such as chromosomal break¬ 
age, fetal abnormalities, and increased incidence of second 
tumors, as well as the unknown effects of prolonged immuno¬ 




Although one of the experimental conditions for 
chemotherapeutic effectiveness is a rapid growth rate, 
pooled data show that cytotoxic drugs benefit women with 
slowly or rapidly progressive breast cancer. Patients 
respond to chemotherapy regardless of estrogen receptor 
status or previous response to endocrine therapy. Pre¬ 
menopausal women and women with a prior response to hor¬ 
monal therapy more often respond to chemotherapy (3) as do 
women with soft tissue metastases (14,p.420). 
Breast cancer responds to all major classes of cyto¬ 
toxic drugs and 15 single agents were found to be effective 
in more than 20% of patients (26). The most frequently used 
drugs whether singly or in combination are the cell-cycle- 
specific agents, MTX and FUra (antimetabolites) and vin¬ 
cristine (a mitosis inhibitor) and the cell-cycle-non-specific 
agents, CTX (an alkylating agent) and adriamycin (an antitumor 
antibiotic) (14,p.412-413). These drugs have independent 
mechanisms of action with non-additive toxicities so they 
lend themselves to combination chemotherapy. 
The Cooper regimen of CMF-VP, reported in 1969, first 
demonstrated the increased effectiveness of combinations. 
Many variations of this regimen have been studied in an 
effort to decrease the doses and number of drugs and, 
therefore, decrease the toxicity. The results show that 
vincristine does not contribute to the response rate (27), 
whereas prednisone may give a slight advantage (28,29). 

15. 
Changes in dosage and scheduling do not seem to affect 
the results (3,14,p.416). Adriamycin is one of the most 
active single agents in breast cancer, but in combination 
it does not seem to affect significantly the response 
rates (3,14,p.419). Further randomized trials are being 
undertaken. 
The response rates for drug combinations were 
40-70% for a duration of 7 to 11 months as compared to the 
20-30% response rates for 3 to 8 months in the cases of 
single agents. Complete response rates, however, were 
still only approximately 15% (30). There has been no 
clear improvement in survival or palliation with combinations 
as opposed to single agents (31). These disappointing 
results with combinations of drugs have led to laboratory 
studies attempting to devise synergistic combination sched¬ 
ules . 
The use of MTX and FUra in combination with leucovorin 
(LV) rescue for the treatment of breast cancer is the basis 
for the present study. In vitro studies with murine leukemic 
cells, L1210, human colon adenocarcinoma cells, HCT-8, 
and hormone dependent human breast cancer cells, 47-DN, 
and in vivo studies in rodents have shown a greater than 
additive cytotoxic effect when FUra follows MTX pretreatment 
(32-36). 
This synergism is in contrast to the theoretical antago¬ 
nism between MTX and FUra on their abilities to inhibit 
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deoxythymidylate (dTMP) synthesis. The presumed major cyto¬ 
toxic effect of FUra is DNA synthesis inhibition as a result 
* 
of inactivation of thymidylate synthetase by 5-fluoro-2'- 
deoxyuridylate (FdUMP) when it forms a ternary complex with 
N ' methylenetetrahydrofolate (N^ • l^CHTHF) and thymidylate 
synthetase. MTX, on the other hand, inhibits dihydrofolate 
reductase and, therefore, prevents the regeneration of 
ISj5,10cHTHF needed for FUra effect. This is the proposed 
evidence against the use of MTX preceding FUra (34). 
However, experimental studies, as indicated above, have 
demonstrated that when FUra follows MTX there is an enhance¬ 
ment of intracelluar accumulation of FUra and its nucleo¬ 
tide derivatives associated with an increase in 5-phospho- 
ribosyl-l-pyrophosphate (PRPP) levels and synergistic antitumor 
effect. This does not occur when MTX and FUra are given simul¬ 
taneously or when FUra precedes MTX. In the human breast can¬ 
cer cell line, 47-DN, accumulation and phosphorylation of FUra 
was increased up to four fold following MTX pretreatment 
resulting in synergistic cell kill (35). 
An alternative mechanism has been proposed to explain the 
interaction of MTX and Fura and is illustrated in Figure 1. 
MTX inhibits dihydrofolate reductase needed for the regeneration 
of tetrahydrofolate pools and thus inhibits de novo purine 
synthesis. PRPP, that would have been used in purine synthesis, 
accumulates and is now available for orotate phosphoribosyl 
transferase to transfer a phosphoribosyl moiety to Fura to 
form 5-fluorouridine monophosphate(FUMP) and other nucleotide 
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derivatives. The subsequent increased incorporation of 
FUra as 5-fluorouracil triphosphate (FUTP) into cellular 
RNA may explain the enhanced cell kill seen when cells are 
exposed to MTX before FUra (33-35). 
The concentration of MTX and the time interval between 
drug administration were important factors in the degree 
of intracellular FUra accumulation and subsequent cyto¬ 
toxicity. In the 47-DN cell line,concentrations of more 
than O.ImM MTX were effective in enhancing FUra accumulation 
and the effectiveness increased with greater MTX pretreat¬ 
ment concentration. In these breast cancer cells, with a 
doubling time of 30 hours, a 24 hour exposure to 10>tM MTX 
resulted in the greatest intracellular FUra accumulation 
and maximum cell kill. The 18 to 24 hour optimal MTX pre¬ 
treatment interval in 47-DN cells is longer than that seen 
in HCT-8 (6-12 hours) and L1210 (3 hours) cells which have 
proportionately shorter doubling times. The dependency of 
the MTX pretreatment interval on cellular growth rates may 
be explained by the fact that MTX inhibits purine synthesis 
only in those cells which are synthesizing DNA. Tumors with 
longer doubling times, like breast cancer whose time to double 
can vary from 3 to 745 days,may have fewer cells synthesizing 
DNA and,therefore,less opportunity for drug synergism dur¬ 
ing a treatment interval (14,p.36,35). 
The timing of LV administration is also important 
since LV rapidly reverses the effects of MTX by decreasing 
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both intracellular PRPP and FUra accumulation. MTX-FUra 
synergism .was only seen when LV followed FUra administra¬ 
tion (35). In addition, hypoxanthine which utilizes PRPP 
was found to reverse totally the enhancement of FUra accumu¬ 
lation when it was added to cells pretreated with MTX (35). 
Trials with sequential MTX and FUra have been undertaken 
in order to apply clinically this experimental data. Pre¬ 
liminary results of MTX followed one hour later by FUra 
and 24 hours later by LV in patients with advanced breast, 
head and neck, and colorectal cancers show favorable re¬ 
sults suggestive of synergism withour major toxicity (37— 
40). However, the longer doubling time of breast cancer 
and the newer laboratory research with 47-DN cells suggest 
that an 18-24 hour MTX pretreatment interval is necessary 
to produce maximum MTX-FUra synergism. Clinical trials are 
needed to study the effect on cytotoxicity of prolonging 
MTX pretreatment intervals. Toxicity of the drugs in the 
new time sequence must first be assessed to see if patients 
can tolerate this drug schedule. 
The present study of seven patients with advanced 
malignancy is a pilot project to evaluate the toxicity of 
the 24 hour MTX pretreatment interval followed by FUra 
and LV, and to determine if oral MTX can sustain effective 
serum levels of more than O.LhM over 24 hours. If this 
therapy can be tolerated, a further study comparing one 
hour and 24 hour sequenced MTX-FUra for use in advanced 
breast cancer can be undertaken. 
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METHODS AND MATERIALS 
Patient Selection 
Seven patients between the ages of 50 and 71 with 
advanced cancer were included in this study between July 
and November 1981. Four patients had disseminated breast 
carcinoma. One patient had locally advanced squamous cell 
carcinoma of the head and neck and two patients had mycosis 
fungoides, one of those with immunoblastic sarcoma of the 
T cell type. The patients all had measurable disease. Two 
had only locally advanced recurrence and five had dissemi¬ 
nated disease with at least two organ systems involved 
(Table 2). All patients had a creatinine clearance —65ml/min. 
a white blood cell (WBC) count s*4500, platelets >130,000, 
and hemoglobin >9.5 gm%. Performance status was not used 
to select patients but six out of seven patients' status 
was two or greater on the Eastern Cooperative Oncology 
Group (ECOG) scale (41) (Table 2 and 3). 
No patient was disqualified on the basis of prior 
therapy and six out of seven patients had responded to at 
least one form of previous treatment. Of the patients with 
breast cancer, three of the four patients were postmenopausal 
at diagnosis. These three patients had been treated with 
mastectomy and were all estrogen receptor positive. The 
fourth patient had not had surgery and estrogen receptor 
status was unknown. All four patients with breast cancer 
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had received prior anti-estrogen therapy. Six out of seven 
of the patients had received prior radiation therapy and 
all the patients had received chemotherapeutic trials with 
multiple drugs. The amount of time since the last chemo¬ 
therapy varied from 7 to 35 days with an average of 23 days. 
Each of the patients had received MTX before this study 
and only one of seven of the patients had not received FUra. 
In fact, six out of seven of the patients had been pre¬ 
viously treated with one hour sequenced MTX-FUra and LV 
as part of an earlier study (37) with the number of courses 
ranging from 1 to 40 (see Table 5) . Four of the six patients 
had received this one hour sequenced MTX-Fura as their last 
chemotherapy before this study (Table 5). 
Drug Regimen 
The patients were treated with a 24 hour sequenced 
schedule of MTX and FUra with LV rescue as follows: Oral 
2 
MTX 50 mg/m every six hours for five doses, i.v. bolus 
2 
FUra 600mg/m one hour after the fifth dose of MTX, and 
2 
oral LV lOmg/m every six hours for six doses starting six 
hours after the fifth dose of MTX. Three out of seven 
patients received this exact drug regimen throughout their 
2 
entire treatment course. Two patients received FUra lgm/m 
2 
and LV 25 mg/m instead for their full course of therapy. 
2 
One patient started at a lower dose of MTX (33mg/m ) but 
2 
the dose was increased to MTX 50 mg/m for the second 




MTX 50 mg/m and FUra 400 mg/m for his third and final 
dose because of side effects (see Results). 
0 
A total of 21 courses of treatment were given with a 
mean of three courses per patient. The interval between 
doses varied according to individual patient tolerance but, 
in general, the re-treatment interval and not the drug 
dosage was altered. 
Study Criteria 
The patients were evaluated according to the ECOG 
toxicity criteria (41) in the categories of leukopenia, 
thrombocytopenia, anemia, nausea and vomiting, diarrhea, 
mucositis, renal function, infection, and fever as shown 
in Table 4. Patients were assigned a score of zero to five 
following each treatment. A toxicity grade of five indicates 
that the toxicity caused the death of the patient. 
MTX serum concentrations were measured one hour before 
and one hour after the fifth dose of MTX by radioimmunoassay 
technique during all 21 courses of therapy. 
Each patient was evaluated for response according to 
the following criteria. A complete response was defined as 
100% disappearance of all metastatic disease at all sites. 
A partial response was regression of more than 50% but less 
than 100% of all measurable disease with no new lesions 
appearing. Advanced disease that showed neither signs of 
response nor progression was considered as stabilization. 

size The appearance of new lesions or 25% increase in 
of existing lesions was considered as progression and 




Serum MTX Concentration 
Seven patients were treated with a total of 21 courses 
of therapy of 24 hour sequenced MTX-FUra with LV rescue. 
The serum MTX concentration one hour before the fifth dose 
of MTX varied from 0.21 M to 3.0 M with a mean of 1.07 M 
and a standard deviation of 0.74. The serum level of MTX 
one hour after the fifth dose varied from 0.52 M to 4.4 M 
with a mean of 2.10 M and a standard deviation of 0.92. These 
MTX concentrations were in the range that resulted in en¬ 
hanced accumulation of FUra and synergistic cytotoxicity in 
laboratory studies. There was no clear relationship between 
the number of prior treatments with MTX or the cumulative 
amount of previous MTX and the present serum MTX levels. 
Patient Response 
Five of the seven patients in the study had dissemi- 
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nated disease, four with breast cancer and one with mycosis 
fungoides, One of these patients died as a result of 
disease progression. Four patients responded with disease 
stabilization. Two were removed from the study after one 
and two months, respectively, when their disease progressed. 
The other two patients continue to be treated with this 
drug regimen, each with three months of stabilization. Of 
the two patients with locally advanced disease (one mycosis 
fungoides, one head and neck cancer), one patient died 
secondary to disease progression. The other patient had a 
partial response lasting two and one half weeks but then 
progressed and was removed from the study. 
The intervals between doses varied from 7 to 42 days; 
only one patient was initially re-treated after 7 days. 
Four of the seven patients received more than two courses 
(average of four) at a mean interval of 23 days. Of the 
patients who received two courses or less, two patients 
died and one progressed while on treatment. No patient 
died or was removed from the study because of toxicity. 
Treatment Toxicity 
The toxicity for the 21 courses of therapy is shown 
in Tables 5 and 6. Two of the 21 courses were associated 
with severe toxicity (ECOG grade 3-4) and in both patients 
this occurred after the second treatment course. Mild to 
moderate toxicity (ECOG grade 1-2) occurred in 11 courses, 
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usually after the first or second treatment, and no toxi¬ 
city at a^Ll occurred in eight treatment courses. 
No patient was leukopenic prior to treatment. Two 
out of seven patients never developed any grade of leukopenia 
and five of seven never developed a WBC count less than 2000. 
One patient developed severe hematologic toxicity (WBC •*: 1000-- 
ECOG grade 4) on her second course of treatment, seven days 
after the first. It was at this time that she developed 
the one infection that occurred during the study. This 
patient went on to receive four more courses of therapy 
with the treatment interval increased from 7 to 14 days. 
Her WBC count remained above 3700. One other patient's 
WBC count fell significantly to 1500 but it rose quickly 
and the patient suffered no consequences as a result. She 
did not receive additional courses because of disease pro¬ 
gression . 
Three out of seven patients were anemic (ECOG grade 1) 
at the start of treatment and anemia was therefore evaluated 
separately as a toxicity. The anemia resulting from the 
treatment was mild,both in patients who were and were not 
anemic prior to treatment, with the exception of one patient 
who developed severe anemia (Hb 8.8 gm%) and required a 
transfusion. This was the same patient that developed grade 4 
leukopenia and it occurred after the same course of treat¬ 
ment. She had no further serious drop in RBC count once 
the treatment interval was lengthened. 
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The nausea/vomiting and diarrhea side effects were 
infrequent and mild. Five of the seven patients experienced 
no nausea or vomiting following any of their treatments. 
Two patients vomited after their first treatment and one 
of these patients experienced nausea after the second. They 
had no difficulty with later treatments. Two of the seven 
patients had diarrhea after the chemotherapy but in each 
case it was mild and without gross bleeding. 
Mucositis was a common side effect, experienced by 
four of the seven patients. Of the 21 courses of therapy, 
two courses resulted in mouth soreness and six caused ulcers. 
The ulcers were never so severe as to interfere with eating 
or the continuation of treatment. 
One patient developed fevers (~101°F) unrelated to in¬ 
fection on the second day of three out of six of her treat¬ 
ments. These fevers lasted one day and did not interfere 
with the patient's treatment. 
One of the patients with mycosis fungoides experienced 
severe skin pain and erythema lasting three to four days 
after his second dose of therapy. This was relieved with a 
reduction to approximately two thirds of the original dose 
of MTX and FUra. 
No patient developed thrombocytopenia or a deteriora¬ 
tion in renal function during the course of treatment. 
The more severe toxicity occurred after the first or 
second dose in each case. Later doses produced milder toxi- 
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city or none at all. In all but two cases no change in 
dose or interval between treatment was necessary to lessen 
toxicity. As previously noted, in the case of severe leu¬ 
kopenia the interval between treatments was lengthened and 
in the case of skin pain the dose was decreased. 
The mean time since the patients were treated with 
chemotherapy was 23 days. The length of time since the last 
treatment was not related to the number of side effects 
experienced. Four out of seven patients had one hour se¬ 
quenced MTX-FUra as their last chemotherapeutic regimen and 
these patients had less toxicity than the other patients. 
There was no clear relationship between the number of pre¬ 
vious courses of one hour sequenced MTX-FUra and toxicity 
(see Table 5). 
Toxicities occurring in more than one system simulta¬ 
neously were experienced by four patients and are shown in 
Table 7. The toxicities that most often occurred together 
were bone marrow suppression and mucositis. The simultaneous 
side effects first occurred after dose one (3 patients) or 
dose two (1 patient) yet the patients still tolerated an 
average of 3.5 courses at 20 day intervals. This compared 
well to the average of four courses at 23 day intervals for 
patients who received more than two courses of therapy. The 
mean serum MTX concentrations for the treatments that caused 
simultaneous toxicity were 0.89 —. 6>\M before the fifth dose of 
MTX and 1.46 —. 6>mM after the fifth dose, both less than the 
mean concentrations for the total 21 courses. 

DISCUSSION 
This small study of seven patients treated with 
a schedule of MTX, FUra, and LV was designed according 
to the sequencing schedule that produced optimal cell 
kill in vitro. The experimental data with 47-DN cells 
and the longer doubling times of breast tumors sug¬ 
gested that a 24 hour sequencing would be necessary 
for maximal synergism between MTX and FUra (35). A 
chemotherapeutic program was chosen that would give 
drug doses similar to that used in previous studies 
with one hour drug sequencing (37,38) but could be 
2 
given out of the hospital. This MTX dose of 250 mg/m 
was given orally in divided doses over 24 hours. The 
schedule maintained the MTX serum level above . LmM 
which is in the range that resulted in enhanced 
cytotoxicity in vitro. 
The pharmacokinetic data of Henderson et al (42) 
2 
for a single oral dose of MTX 50 mg/m with decay can 
be extrapolated according to the dose schedule of MTX 
2 
given in this study, 50 mg/m p.o. every six hours for 

five doses. Based on these data one would expect the 
serum MTX concentration to be 0.26 M at 23 hours (before 
the fifth dose) and 0.46 M at 25 hours (after the fifth 
dose) as shown in Figure 2. However, the actual mean 
concentrations in this study were well over two standard 
deviations above this model and were instead in the 
2 
range of an i.v. bolus of MTX 250 mg/m given 24 hours 
earlier. The fact that the serum concentrations were 
above that extrapolated from the Henderson curve for 
2 
one dose of oral MTX 50 mg/m suggests that repeated 
oral administration may alter MTX clearance. This oral 
dose schedule proved feasible for further use. 
The present study also evaluated the effect on 
host toxicity of prolonging the MTX pretreatment in¬ 
terval according to in vitro studies. Prior studies 
with a lengthened pretreatment interval have shown 
increased toxicity that outweighed the therapeutic 
advantage of greater tumor cell kill. 

Solan et al (43) reported on a small, uncontrolled trial 
in colorectal cancer patients using similar doses of intra¬ 
venous MTX and FUra with four hour sequencing,given at 
weekly intervals. They found unacceptable myelosuppression and 
attributed it to the longer MTX pretreatment interval. An¬ 
other study that compared MTX and FUra schedules in tumor¬ 
bearing mice found that although 24 hour sequencing resulted 
in maximal cell kill, it also increased early deaths from 
toxicity more than six times over the other two drug sched¬ 
ules (44). 
In contrast, the present study shows that 24 hour se¬ 
quenced MTX-Fura can be well tolerated with only mild and 
transient toxicity. No patient stopped therapy because 
of intolerable side effects and there were no drug related 
deaths. No toxicity occurred with 38% of the treatment 
courses. Bone marrow suppression and mucositis were the 
most common side effects with mild to moderate leukopenia 
and mucositis occurring in 27% and 38% of courses, respec¬ 
tively (Table 5). Those patients with more than two courses 
tolerated an average of four treatments with a mean treat¬ 
ment interval of 23 days. The patients with simultaneous 
toxicity developed this early on in treatment and were still 
able to tolerate an average of 3.5 courses at 20 day inter¬ 
vals. The occurrence of toxicity was not related to either 
cumulative drug dose or greater than average serum MTX con¬ 
centration. Only one patient required a dose reduction and 
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one patient required a lengthening of the re-treatment 
interval#from 7 to 14 days. 
Why is there such a great difference between the 
toxicity results of the present study and that of the 
trial of Solan et al (43)? Unacceptable myelosuppression 
occurred in the study done by Solan et al when the interval 
between treatment courses was seven days. Only one patient 
in the present study experienced severe bone marrow sup¬ 
pression, and it was after the same seven day re-treatmennt 
interval schedule. This patient had no further problems 
once the interval was lengthened; no other patient had such 
a short interval between courses or had such severe side 
effects. Toxicity may be related to re-treatment 
interval rather than to the prolonged interval between 
MTX and FUra administration. Lengthening the interval 
between treatment courses to at least 14 days makes this 
chemotherapeutic regimen well tolerated. 
Another possible explanation for the different results 
in the two studies is that Solan et al give no data on renal 
function; in this study no patient was accepted with a 
creatinine clearance less than 65. The patients in Solan's 
study may have had a decreased MTX clearance and thus a 
worsening of toxicity. 
In addition, individual variations in circulating 
levels of thymidine and "salvage" purines may account for 
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differences in toxicities. Since MTX inhibits both thymi- 
dylate synthesis and de novo purine synthesis, the addition 
of thymidine or purines such as hypoxanthine can potential¬ 
ly prevent the toxic effects of MTX. Howell et al (45) 
found that the normal physiologic range of plasma hypoxan¬ 
thine is within the concentration range of hypoxanthine 
that reverses FUra accumulation in 47-DN MTX pretreated 
cells (0.1-10/mM) (35). They also found that the hypoxan¬ 
thine concentrations in freshly aspirated bone marrow spec¬ 
imens were so high that protection against MTX depended 
only on thymidine availability. In culture, small changes 
in thymidine concentrations resulted in large differences 
in the degree of MTX toxicity. In two small, uncontrolled 
studies such as the present one and that by Solan et al, 
differences in serum thymidine concentrations could account 
for the variability in clinical toxicity. The patients in 
this study may have thymidine and hypoxanthine concentra¬ 
tions in the range to selectively protect bone marrow 
precursors. 
The response rate in this study is poor compared with 
other reported drug regimens. Gerwitz and Cadman (37) 
achieved a response rate of 53% (complete or partial 
responses) with 1 hour sequenced MTX-FUra. In this study 
only one patient (14%) achieved an objective response and 
for only two and a half weeks. However,the patients in 
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this trial had far advanced malignancy and had received 
many prior chemotherapeutic trials; they were therefore 
less likely to respond to further treatment. The MTX- 
FUra synergism observed in tissue culture of human breast 
cancer was maximal with a 2 4 hour pretreatment interval, 
suggesting that this protocol may be very effective as 
an initial therapy in previously untreated women with 
advanced breast cancer. Nevertheless, the extreme varia¬ 
tion in breast cancer growth rate may indicate that the 
optimal MTX pretreatment interval will vary from patient 
to patient. 
Although this study is small, the clinical results 
show that the 24 hour sequenced schedule of MTX and FUra 
with LV rescue is well tolerated. This regimen can now 
be safely evaluated in a larger clinical trial and compared 
with one hour sequenced MTX and FUra. Advanced breast 
cancer is incurable; but the search for new and more 
effective chemotherapeutic programs is moving toward the 
goal of increasing the duration of symptom-free and abso¬ 
lute survival, while decreasing the morbidity of treatment. 
This study is a small step toward that goal. 

Table 1 Survival of Patients with Breast Cancer Relative to Histologic Stage (3) 
Histologic Staging 
All patients 
Negative axillary lymph nodes 
Positive axillary lymph nodes 
1-3 positive axillary lymph nodes 
> 4 positive axillary lymph nodes 
Crude 5-Year 
Survival (%) Disease-Free 
5 yr 10 yr Survival (%) 
63.5 45.9 60.3 
78.1 64.9 82.3 
46.5 24.9 34.9 
62.2 37.5 50.0 
32.0 13.4 21.1 
Table 2 Organs Involved with Metastatic Disease—Seven Patients 
Table 3 ECOG Performance Status Key (41) 
Performance Status Scale 
0—Normal activity 
1— Symptoms but ambulatory 
2— In bed <50% of time 
3— In bed >50% Of time 





4—100% bedridden 1 
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TABLE 4 ECOG TOXICITY CRITERIA (41) Clinic Form 
0 1 2 3 4 
Leuko¬ 
penia 
WBC X 10’ 


























Sx of anemia Req transfusions 
Infection None No active Rx Requires active Rx Debilitating Life threatening 






















c obst uropathy 
N & V None Nausea N <fc V controllable Vomiting intractable 
Diarrhea None No dehydration Dehydration Grossly bloody 
Skin & 
Mucosa Stomatitis None Soreness Ulcers—can eat Ulcers—cannot eat 
Fever <37.5°C ^38°C «100 4CF) >38°C (>100.4° F) 
Severe c chills 
p> 40°C) 
Fever c hypotensior 
— 
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Table 6. Clinical Toxicity—21 Courses 
BCOG Grade 
Leukopenia 0 1 2 3 4 
Nausea/ 
Vomiting 18 1 2 0 
Diarrhea 18 3 0 0 
Mucositis 13 2 6 0 
Fever 19 0 3 0 0 










4 4 1 1 0 
Table 7.—Simultaneous Toxicity- -Four Patients 




Occurred After Dose # 2. 3. 4. 1. 1. 1. 2. 
Leukopenia/Anemia X X X X X 
Nausea/Vomiting X X 
Diarrhea X X X 





Proposed interaction between MIX and FUra metabolism 
Adapted from Cadrran, Heimer, and Benz (34) 
Pyrimidine Synthesis Purine Synthesis 
Glutamine + HCO Glutamine 
H. 










FdUMP directly inhibits enzyme 2 in the 
presence of THF. MIX inhibits enzyme 3 
and dTMP synthesis when the THF pools are 
depleted.The reduction of THF pools also 
leads to an inhibition of purine synthesis 
and then an accumulation of PRPP.PRPP is 
used in the conversion of FUra to FUMP and 









Broken arrcws represent multiple enzymatic steps 
^■represents inhibition of step 
Enzymatic Steps 
1. orotate phosphoribosyltransferase 
2. thymidylate synthetase 
3. dihydro folate reductase 
4. glycinamide ribonucleotide transform/lase 
5. amino imidazole carboxamide ribonucleotide transformylase 







FIGURE 2 MTX Pharmacokinetic Data 
The dotted lines represent the data of 
Henderson et al (42) for a single dose of 
MTX 50 mg/m2 p.o. and 250 mg/m^ i.v. with 
decay. The curve for the MTX dose schedule 
in this study, 50 mg/m2 p.o. Q 6 hours x 5, 
has been extrapolated from the 50 mg/m^p.o. 
single dose curve. Serum MTX concentrations ' 
were measured one hour before and one hour [ 
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